Ipca Laboratories earnings beat driven by domestic share gains, exports and API recovery

Investment View and Valuation

Motilal Oswal Financial Services Limited (MOFSL) reiterated its Buy recommendation on Ipca Laboratories following a broad-based 1QFY27 earnings beat. The broker attributes the outperformance to strong exports and API sales, supported by improved operating leverage. It expects earnings momentum to continue, led by domestic formulation market-share gains, increased export offtake, an improving API outlook and favourable currency movements.

MOFSL values Ipca Laboratories at 30 times 12-month forward earnings to derive a target price of Rs2,060, compared with the current market price of Rs1,734.

1QFY27 Financial Performance

Ipca Laboratories reported sales growth of 20.8 per cent year on year to Rs27.9 billion, exceeding MOFSL's Rs25.9 billion estimate by 8 per cent. Gross margin expanded by 140 basis points year on year to 71.4 per cent. EBITDA increased 61 per cent year on year to Rs6.7 billion, 25 per cent above the broker's Rs5.4 billion estimate, while EBITDA margin expanded by 600 basis points to 24 per cent against the estimated 20.7 per cent. Adjusted PAT rose 72.3 per cent year on year to Rs4 billion, beating MOFSL's Rs3 billion expectation by 34 per cent.

Formulation and API Business Performance

Domestic Formulations

Formulation sales rose 19 per cent year on year to Rs16.9 billion, representing 61 per cent of total sales. Domestic formulation sales increased 13 per cent to Rs10.8 billion, or 39 per cent of sales, reflecting demand tailwinds and superior execution versus the industry.

Management said domestic growth was driven by approximately 5 per cent volume growth, 5 per cent pricing growth and 2 per cent contribution from new launches. Growth by therapy area was as follows:

• Urology: 25 per cent
• Central nervous system: 19 per cent
• Cardiovascular and anti-diabetes: 17 per cent
• Dermatology: 17 per cent
• Ophthalmology: 17 per cent
• Pain management: 13 per cent

The chronic portfolio grew 17.2 per cent, while the acute portfolio grew 8.9 per cent. Ipca Laboratories had approximately 7,000 medical representatives and plans to add about 200 during FY27 to support new divisions.

Export Formulations and APIs

Export formulation sales increased 34 per cent year on year to Rs6 billion, accounting for 22 per cent of sales. Generic formulation exports grew 27 per cent to Rs3.4 billion, branded exports increased 16 per cent to Rs1.4 billion and institutional business rose 107 per cent to Rs1.2 billion. MOFSL notes that institutional growth benefited from around Rs400 million of shipments deferred from March 2026 to April 2026.

API sales recovered after two weak quarters, rising 30 per cent to Rs4.2 billion. Export API sales grew 33 per cent to Rs3.3 billion, while domestic API sales increased 20 per cent to Rs914 million.

Subsidiary Performance

Revenue from subsidiaries grew 19 per cent to Rs6.7 billion. Unichem's US business grew 27 per cent, including 9 per cent growth in its own portfolio.

Management Guidance and Growth Initiatives

Management upgraded FY27 overall revenue growth guidance to 14–16 per cent from 12–13 per cent and raised consolidated EBITDA margin guidance to about 23 per cent from about 22 per cent. It retained domestic growth guidance of 12–13 per cent and Unichem's FY27 guidance of 10 per cent revenue growth and a 13 per cent EBITDA margin.

• Management expects US business growth of about 15–17 per cent over the next few years.
• The company plans 7–8 US product launches and 4–5 ANDA filings annually.
• Management does not expect near-term margin pressure despite anticipated API price increases, citing an expected decline in material cost as a proportion of sales.
• Ipca Laboratories plans an additional Rs1 billion FY27 investment in biotech pilot facilities and research and development.

MOFSL Estimates and Outlook

MOFSL raised its earnings estimates by 14 per cent and 4 per cent for FY26 and FY27, respectively, reflecting a stronger outlook for export formulations and APIs and better operating leverage.